pharmatimes.com

pharmatimes.com Β·

Negative

smc backs first line metastatic bladder cancer combination after trial results

TAX_FNCACT_INVESTIGATORTAX_DISEASE_BLADDER_CANCERSOC_POINTSOFINTEREST_UNIVERSITYTAX_ETHNICITY_SCOTTISH

The full article is on the original publisher site. This page only shows the headline and a very short excerpt.

About the publisher

pharmatimes.com is one of the en-language news outlets that News Analysis aggregates. Coverage from this source appears in our global feed alongside the publisher's own reporting.

Topic context

pharmatimes.com files this story under "tax fncact investigator" in the GDELT knowledge graph. News Analysis surfaces coverage based on the same open classification taxonomy.

smc backs first line metastatic bladder cancer combination after trial results | pharmatimes.com β€” News Analysis